[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100514215":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":35,"centralContacts":39,"locations":44,"responsibleParty":105,"collaborators":107,"id":113,"slug":23,"hasResults":114,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":114,"sex":120,"minAge":121,"maxAge":23,"enrollmentInfo":122,"targetDuration":23,"studyType":125,"phases":126,"briefSummary":128,"conditions":129,"keywords":138,"overallStatus":46,"whyStopped":23,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":153},{"fullName":5,"class":6},"Washington University School of Medicine","OTHER",[8,15],{"label":9,"type":6,"description":10,"interventionNames":11},"Cervical Cancer","* Patients will have blood and tumor collected at various time points throughout participation in the study.\n* Patients will have standard of care imaging obtained at various time points and a diffusion basis spectrum imaging (DBSI) MRI will be obtained at the end of standard of care MRI.",[12,13,14],"Other: Tumor collection via biopsy","Other: Blood collection","Device: Diffusion basis spectrum imaging (DBSI) magnetic resonance imaging (MRI)",{"label":16,"type":6,"description":10,"interventionNames":17},"Pancreatic Cancer",[12,13,14],[19,24,28],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"Tumor collection via biopsy","Cervical cancer: Pre-radiation therapy, 1 week after beginning radiation therapy, 3 weeks after beginning radiation therapy, and recurrence.\n\nPancreatic cancer: pre-stereotactic body radiotherapy, 12 weeks after completion of radiotherapy, and recurrence.",[9,16],null,{"type":6,"name":25,"description":26,"armGroupLabels":27,"otherNames":23},"Blood collection","Cervical cancer: pre-radiation therapy, 1 week after beginning radiation therapy, 3 weeks after beginning radiation therapy, 6 weeks after completing radiation therapy, 12 weeks after completing radiation therapy, and recurrence.\n\nPancreatic cancer: pre-stereotactic body radiotherapy, 6 weeks after completion of radiotherapy, 12 weeks after completion of radiotherapy, surgery (if applicable), and recurrence",[9,16],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"DEVICE","Diffusion basis spectrum imaging (DBSI) magnetic resonance imaging (MRI)","Cervical cancer: initial staging, 12 weeks after completing radiation therapy, and recurrence.\n\nPancreatic cancer: initial staging, stereotactic body radiotherapy (SBRT) simulation, 12 weeks after completing radiation therapy, and recurrence.\n\nThe imaging will be performed when possible.",[9,16],[34],"DBSI MRI",[36],{"name":37,"affiliation":5,"role":38},"Cliff Robinson, M.D.","PRINCIPAL_INVESTIGATOR",[40],{"name":37,"role":41,"phone":42,"phoneExt":23,"email":43},"CONTACT","314-362-8567","clifford.robinson@wustl.edu",[45],{"facility":5,"status":46,"city":47,"state":48,"zip":49,"country":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"RECRUITING","St Louis","Missouri","63110","United States",{"type":52,"coordinates":53},"Point",[54,55],-90.19789,38.62727,{"lat":55,"lon":54},[58,59,60,63,65,67,69,71,73,75,77,79,81,83,85,87,89,91,93,95,97,99,101,103],{"name":37,"role":41,"phone":42,"phoneExt":23,"email":43},{"name":37,"role":38,"phone":23,"phoneExt":23,"email":23},{"name":61,"role":62,"phone":23,"phoneExt":23,"email":23},"Carl DeSelm, M.D., Ph.D.","SUB_INVESTIGATOR",{"name":64,"role":62,"phone":23,"phoneExt":23,"email":23},"Stephanie Markovina, M.D., Ph.D.",{"name":66,"role":62,"phone":23,"phoneExt":23,"email":23},"Julie Schwarz, M.D., Ph.D.",{"name":68,"role":62,"phone":23,"phoneExt":23,"email":23},"Jessika Contreras, M.D.",{"name":70,"role":62,"phone":23,"phoneExt":23,"email":23},"Dineo Khabele, M.D.",{"name":72,"role":62,"phone":23,"phoneExt":23,"email":23},"David DeNardo, Ph.D.",{"name":74,"role":62,"phone":23,"phoneExt":23,"email":23},"Hyun Kim, M.D.",{"name":76,"role":62,"phone":23,"phoneExt":23,"email":23},"Kian-Huat Lim, M.D.",{"name":78,"role":62,"phone":23,"phoneExt":23,"email":23},"Hua Li, Ph.D.",{"name":80,"role":62,"phone":23,"phoneExt":23,"email":23},"Albert Lai, Ph.D.",{"name":82,"role":62,"phone":23,"phoneExt":23,"email":23},"Philip Payne, Ph.D.",{"name":84,"role":62,"phone":23,"phoneExt":23,"email":23},"Doug Caruthers, M.S.",{"name":86,"role":62,"phone":23,"phoneExt":23,"email":23},"Esther Lu, Ph.D.",{"name":88,"role":62,"phone":23,"phoneExt":23,"email":23},"Lei Liu, Ph.D.",{"name":90,"role":62,"phone":23,"phoneExt":23,"email":23},"Andrea Hagemann, M.D.",{"name":92,"role":62,"phone":23,"phoneExt":23,"email":23},"Lindsay Kuroki, M.D.",{"name":94,"role":62,"phone":23,"phoneExt":23,"email":23},"Leslie Stuart Massad, M.D.",{"name":96,"role":62,"phone":23,"phoneExt":23,"email":23},"Carolyn McCourt, M.D.",{"name":98,"role":62,"phone":23,"phoneExt":23,"email":23},"Maggie Mullen, M.D.",{"name":100,"role":62,"phone":23,"phoneExt":23,"email":23},"Matthew Powell, M.D.",{"name":102,"role":62,"phone":23,"phoneExt":23,"email":23},"Brooke Sanders, M.D.",{"name":104,"role":62,"phone":23,"phoneExt":23,"email":23},"Premal Thaker, M.D.",{"type":106,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR",[108,111],{"name":109,"class":110},"National Cancer Institute (NCI)","NIH",{"name":112,"class":6},"The Foundation for Barnes-Jewish Hospital","100514215",false,"NCT05975593","MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial","MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial (METEOR-CRATR)","METEOR-CRATR","Inclusion Criteria:\n\n* Confirmation of intent to receive radiotherapy for one of the following diagnoses:\n\n  * Cervical cancer\n  * Pancreatic cancer\n* ECOG performance status ≤ 2\n* At least 18 years old\n* Able to understand and willing to sign an IRB-approved written informed consent document\n\nExclusion Criteria:\n\n* Any issue (medical, anatomic, other) that might preclude safe acquisition of biospecimens at the discretion of the treating physician","ALL","18 Years",{"count":123,"type":124},60,"ESTIMATED","INTERVENTIONAL",[127],"NA","This study is a dynamically adjustable prospective longitudinal study designed to capture biospecimen (biopsy, blood, surgical) and multimodal treatment-related data (imaging, dosimetry, clinical) before, during, and after treatment with definitive-intent chemoradiotherapy for patients with locally advanced cervical and pancreatic cancer.",[130,131,132,133,134,9,135,16,136,137],"Locally Advanced Cervical Carcinoma","Locally Advanced Cervical Cancer","Locally Advanced Pancreas Cancer","Locally Advanced Pancreatic Carcinoma","Locally Advanced Pancreatic Cancer","Pancreas Cancer","Cancer of the Cervix","Cancer of the Pancreas",[139,140,141,142,143],"Radiotherapy","Chemotherapy","Cervical cancer","Pancreatic cancer","Biospecimen","2025-11-07",{"date":146,"type":147},"2025-11-12","ACTUAL",{"date":149,"type":147},"2024-01-11",{"date":151,"type":124},"2032-12-31",{"name":5,"class":6},1]